Clinical Trials in Boston

Showing 12361-12380 of 15,299 trials

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

NCT01705145

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), of ivacaftor in children with cystic fibrosis (CF) who are 2 through 5 years of age and have a CF Transmembrane Conductance Regulator (CFTR) gating mutation in at least 1 allele. Part A is designed to evaluate the safety and PK of multiple-dose administration of ivacaftor in participants 2 through 5 years of age and to confirm the doses for Part B. Part B is designed to evaluate the safety, PK, PD, and efficacy of ivacaftor in participants 2 through 5 years of age.

Cystic Fibrosis

Vertex Pharmaceuticals Incorporated35 participantsStarted Jan 2013

Birmingham, Alabama, United States • Aurora, Colorado, United States • Atlanta, Georgia, United States +17 more locations

COMPLETEDPhase 3< 1 mile

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

NCT00396097

To demonstrate that an individualized, formula-based Genotropin regimen for children with Idiopathic Short Stature will lead to a targeted height gain (to reach the target of 10th percentile (%), or -1.3 SDS) during 24 months of treatment. The endpoint at 4 years is to explore treatment efficiency over four years of two formula-based dose regimens (sub-arms) compared to standard treatment

Idiopathic Short Stature

Pfizer316 participantsStarted Dec 2006

Little Rock, Alaska, United States • Little Rock, Arkansas, United States • Los Angeles, California, United States +40 more locations

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

Find Trials by Condition in Boston

Medigus Ultrasonic Surgical Endostapler (MUSE) Registry

HIV/AIDS, Severe Mental Illness and Homelessness

TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

Effect of NeuroAD on the Cognitive Function of Alzheimer Patients

Coenzyme Q10 in Huntington's Disease (HD)

Optimal Method of Fascial Closure in High Risk Patients Undergoing Laparotomy

Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Niacin Plus Statin to Prevent Vascular Events

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis

Sober Network IPT for Perinatal Women With Comorbid Substance Use and Depression

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Cross-sectional Study for Identification and Description of Severe Asthma Patients

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients